OpGen-image

OpGen

US: OPGN

Market Cap$38.3m

Last Close $0.98

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

More OpGen content >

Investment summary

OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. With the recent 510(k) clearance of the Acuitas AMR Gene Panel in bacterial isolates, OpGen has reached the next stage of its corporate evolution. As a reminder, the panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens and provides genomic profile data much quicker than traditional methods (2.5 hours versus one to four days).

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 3.5 (11.7) (11.9) (737.57) N/A N/A
2020A 4.2 (22.0) (25.3) (157.41) N/A N/A
2021E 3.8 (26.2) (30.9) (85.48) N/A N/A
2022E 8.3 (23.2) (25.5) (0.63) N/A N/A
Industry outlook

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Last updated on 18/01/2022
Content on OpGen
OpGen – FDA clearance a step forward
Healthcare | Update | 17 November 2021
OpGen-image
OpGen – AMR Gene Panel clearance expected shortly
Healthcare | Update | 18 August 2021
OpGen-image
View more
Register to receive research on OpGen as it is published
Share price graph
Balance sheet
Forecast net debt (US$m) 7.2
Forecast gearing ratio (%) 30
Price performance
%
1m
3m
12m
Actual (9.1) (52.1) (52.6)
Relative* (8.2) (53.0) (60.9)
52-week high/low US$3.6/US$1.0
*% relative to local index
Key management
Oliver Schacht CEO